Cargando…

Analytic Characterization of the Herpes Simplex Virus Type 2 Epidemic in the United States, 1950–2050

BACKGROUND: We analytically characterized the past, present, and future levels and trends of the national herpes simplex virus type 2 (HSV-2) epidemic in the United States. METHODS: A population-level mathematical model was constructed to describe HSV-2 transmission dynamics and was fitted to the da...

Descripción completa

Detalles Bibliográficos
Autores principales: Ayoub, Houssein H, Amara, Ibtihel, Awad, Susanne F, Omori, Ryosuke, Chemaitelly, Hiam, Abu-Raddad, Laith J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274361/
https://www.ncbi.nlm.nih.gov/pubmed/34262986
http://dx.doi.org/10.1093/ofid/ofab218
_version_ 1783721542900776960
author Ayoub, Houssein H
Amara, Ibtihel
Awad, Susanne F
Omori, Ryosuke
Chemaitelly, Hiam
Abu-Raddad, Laith J
author_facet Ayoub, Houssein H
Amara, Ibtihel
Awad, Susanne F
Omori, Ryosuke
Chemaitelly, Hiam
Abu-Raddad, Laith J
author_sort Ayoub, Houssein H
collection PubMed
description BACKGROUND: We analytically characterized the past, present, and future levels and trends of the national herpes simplex virus type 2 (HSV-2) epidemic in the United States. METHODS: A population-level mathematical model was constructed to describe HSV-2 transmission dynamics and was fitted to the data series of the National Health and Nutrition Examination Survey. RESULTS: Over 1950–2050, antibody prevalence (seroprevalence) increased rapidly from 1960, peaking at 19.9% in 1983 in those aged 15–49 years, before reversing course to decline to 13.2% by 2020 and 8.5% by 2050. Incidence rate peaked in 1971 at 11.9 per 1000 person-years, before declining by 59% by 2020 and 70% by 2050. Annual number of new infections peaked at 1 033 000 in 1978, before declining to 667 000 by 2020 and 600 000 by 2050. Women were disproportionately affected, averaging 75% higher seroprevalence, 95% higher incidence rate, and 71% higher annual number of infections. In 2020, 78% of infections were acquired by those 15–34 years of age. CONCLUSIONS: The epidemic has undergone a major transition over a century, with the greatest impact in those 15–34 years of age. In addition to 47 million prevalent infections in 2020, high incidence will persist over the next 3 decades, adding >600 000 new infections every year.
format Online
Article
Text
id pubmed-8274361
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-82743612021-07-13 Analytic Characterization of the Herpes Simplex Virus Type 2 Epidemic in the United States, 1950–2050 Ayoub, Houssein H Amara, Ibtihel Awad, Susanne F Omori, Ryosuke Chemaitelly, Hiam Abu-Raddad, Laith J Open Forum Infect Dis Major Article BACKGROUND: We analytically characterized the past, present, and future levels and trends of the national herpes simplex virus type 2 (HSV-2) epidemic in the United States. METHODS: A population-level mathematical model was constructed to describe HSV-2 transmission dynamics and was fitted to the data series of the National Health and Nutrition Examination Survey. RESULTS: Over 1950–2050, antibody prevalence (seroprevalence) increased rapidly from 1960, peaking at 19.9% in 1983 in those aged 15–49 years, before reversing course to decline to 13.2% by 2020 and 8.5% by 2050. Incidence rate peaked in 1971 at 11.9 per 1000 person-years, before declining by 59% by 2020 and 70% by 2050. Annual number of new infections peaked at 1 033 000 in 1978, before declining to 667 000 by 2020 and 600 000 by 2050. Women were disproportionately affected, averaging 75% higher seroprevalence, 95% higher incidence rate, and 71% higher annual number of infections. In 2020, 78% of infections were acquired by those 15–34 years of age. CONCLUSIONS: The epidemic has undergone a major transition over a century, with the greatest impact in those 15–34 years of age. In addition to 47 million prevalent infections in 2020, high incidence will persist over the next 3 decades, adding >600 000 new infections every year. Oxford University Press 2021-04-29 /pmc/articles/PMC8274361/ /pubmed/34262986 http://dx.doi.org/10.1093/ofid/ofab218 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Major Article
Ayoub, Houssein H
Amara, Ibtihel
Awad, Susanne F
Omori, Ryosuke
Chemaitelly, Hiam
Abu-Raddad, Laith J
Analytic Characterization of the Herpes Simplex Virus Type 2 Epidemic in the United States, 1950–2050
title Analytic Characterization of the Herpes Simplex Virus Type 2 Epidemic in the United States, 1950–2050
title_full Analytic Characterization of the Herpes Simplex Virus Type 2 Epidemic in the United States, 1950–2050
title_fullStr Analytic Characterization of the Herpes Simplex Virus Type 2 Epidemic in the United States, 1950–2050
title_full_unstemmed Analytic Characterization of the Herpes Simplex Virus Type 2 Epidemic in the United States, 1950–2050
title_short Analytic Characterization of the Herpes Simplex Virus Type 2 Epidemic in the United States, 1950–2050
title_sort analytic characterization of the herpes simplex virus type 2 epidemic in the united states, 1950–2050
topic Major Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274361/
https://www.ncbi.nlm.nih.gov/pubmed/34262986
http://dx.doi.org/10.1093/ofid/ofab218
work_keys_str_mv AT ayoubhousseinh analyticcharacterizationoftheherpessimplexvirustype2epidemicintheunitedstates19502050
AT amaraibtihel analyticcharacterizationoftheherpessimplexvirustype2epidemicintheunitedstates19502050
AT awadsusannef analyticcharacterizationoftheherpessimplexvirustype2epidemicintheunitedstates19502050
AT omoriryosuke analyticcharacterizationoftheherpessimplexvirustype2epidemicintheunitedstates19502050
AT chemaitellyhiam analyticcharacterizationoftheherpessimplexvirustype2epidemicintheunitedstates19502050
AT aburaddadlaithj analyticcharacterizationoftheherpessimplexvirustype2epidemicintheunitedstates19502050